Melatonin for chronic muscle and joint pain: modest relief with sleep benefits, study finds

Original publisher Nature reports on a meta-analysis evaluating melatonin for chronic muscle and joint pain. Analyzing 23 clinical trials with more than 2,000 participants, the review finds modest improvements in both pain and sleep, particularly among people who already have sleep problems. It also highlights wide variations in dose and treatment duration, and calls for larger, well-designed trials to determine who benefits most.

• Melatonin reduces chronic muscle and joint pain by about nine points on a 100-point scale on average, with concurrent sleep improvements.
• Most trials included participants with sleep problems, so it is unclear whether benefits extend to those without sleep issues.
• Dose ranges from 1 mg to 10 mg and the optimal dose and treatment length remain unknown.
• Short-term safety is generally good, but side effects such as daytime sleepiness and dizziness can occur; medical advice is advised for people with liver or kidney conditions or autoimmune diseases; access to melatonin varies by country (OTC in the US, prescription in the UK).

Overview

Melatonin is widely used to treat insomnia and jet lag, but a comprehensive review reported by Nature examines its potential to ease chronic muscle and joint pain. By pooling results from 23 clinical trials encompassing more than 2,000 participants, the study assesses whether melatonin can reduce pain in long-term musculoskeletal conditions and whether it also improves sleep. The authors emphasize that the observed pain relief is modest and that sleep improvements were frequently noted, raising the possibility that sleep improvement may contribute to pain relief in some individuals.

Background: why melatonin might affect pain

Melatonin is a hormone produced by the pineal gland that regulates the sleep-wake cycle. Beyond sleep regulation, researchers propose that melatonin may dampen pain signaling in the brain and spinal cord, reduce inflammation, calm overactive nerves, and shield cells from oxidative stress. These mechanisms provide a theoretical basis for testing melatonin as a pain-modifying intervention, particularly for chronic pain where sleep disturbance and pain interact in a bidirectional loop.

Study design and scope

The analysis synthesized data from 23 randomized or quasi-randomized clinical trials. The trials evaluated melatonin for chronic muscle and joint pain and pain after surgery. Most included individuals who already had sleep problems, which means the participant pool may not represent all people with chronic musculoskeletal pain. The trials varied in melatonin doses, with a wide range from 1 mg to 10 mg daily, and different treatment durations. No trials directly compared melatonin with standard anti-inflammatory medications, so direct efficacy against established pain therapeutics cannot be drawn from this dataset.

Key findings

Across the included studies, melatonin produced improvements in both pain and sleep outcomes. On average, pain scores declined by roughly nine points on a 100-point scale. This magnitude is within the range reported for some anti-inflammatory drugs in similar pain contexts, though the trials were not head-to-head comparisons with those therapies. Sleep improvements were consistently reported in many trials, underscoring the interconnectedness of sleep and pain. However, the overall effect size for pain was described as modest, and the consistency of the effect across all patient groups remains uncertain.

Who benefits and how dosing matters

Several nuances emerged. The trials mainly enrolled people with preexisting sleep problems, so it is unclear whether melatonin's analgesic effects differ between those with sleep disturbances and those without. The relationship between durable sleep improvement and pain relief is not fully established. Dosing varied widely from 1 mg to 10 mg, and the data did not allow a clear determination of the optimal dose or duration for pain relief. Some hints suggested longer treatment might yield greater benefit in chronic pain, but this conclusion rests on only a few studies, making it prone to uncertainty.

Safety considerations and regulatory context

Melatonin is generally considered safe for short-term use. Reported side effects include daytime sleepiness, dizziness, headaches, and nausea. People with liver or kidney conditions, or autoimmune diseases such as rheumatoid arthritis, should consult a health professional before taking melatonin. Regulatory status varies by country: in the United States it is sold as a dietary supplement and widely available without medical advice, whereas in the United Kingdom it is prescription-only and licensed specifically for short-term sleep problems and jet lag. The review highlights that this discrepancy could influence who might consider melatonin for pain management in different regions.

Limitations and uncertainties

Limitations include the heterogeneity of the included trials, the broad dose range, and the lack of stratified reporting that would show results separately for sleep-impaired versus non-sleep-impaired participants. Because most trials did not stratify results by sleep status, it remains unclear whether melatonin is more beneficial for individuals with sleep problems or if similar effects occur regardless of baseline sleep quality. Moreover, there are no direct comparisons with standard pain therapies, so the relative value of adding melatonin to existing regimens is uncertain.

Implications for practice and future research

At present, melatonin may offer modest relief for some people with chronic muscle and joint pain, particularly when sleep problems are part of the clinical picture. It is unlikely to replace established pain treatments but could be considered as an adjunct in selected cases. To determine which patients stand to gain the most, larger, well-designed randomized trials are essential. Future studies should aim to identify specific dosing regimens, patient subgroups defined by sleep quality, and longer treatment durations while comparing melatonin to standard analgesics or adding it to combination therapies.

Conclusion

The new synthesis suggests that melatonin has potential as a supplementary approach to managing chronic musculoskeletal pain and sleep disturbances. The effect on pain is modest, and the benefits appear intertwined with sleep improvements. Clinicians should weigh the modest analgesic potential against safety considerations and regulatory differences, and researchers should pursue more rigorous, stratified trials to clarify who benefits most and under what dosing conditions.